Pfizer (PFE) : First Quadrant L Pca reduced its stake in Pfizer by 4.77% during the most recent quarter end. The investment management company now holds a total of 1,594,536 shares of Pfizer which is valued at $53,050,213 after selling 79,895 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Apr 20, 2016.Pfizer makes up approximately 1.14% of First Quadrant L Pca’s portfolio.
Pfizer opened for trading at $33.25 and hit $33.5 on the upside on Friday, eventually ending the session at $33.27, with a gain of 0.09% or 0.03 points. The heightened volatility saw the trading volume jump to 2,61,37,321 shares. Company has a market cap of $205,746 M.
Other Hedge Funds, Including , Stokes Hubbell Capital Management boosted its stake in PFE in the latest quarter, The investment management firm added 20,567 additional shares and now holds a total of 42,534 shares of Pfizer which is valued at $1,415,106. Pfizer makes up approx 0.64% of Stokes Hubbell Capital Management’s portfolio.Deane Retirement Strategies reduced its stake in PFE by selling 1,390 shares or 2.94% in the most recent quarter. The Hedge Fund company now holds 45,956 shares of PFE which is valued at $1,528,956. Pfizer makes up approx 1.44% of Deane Retirement Strategies’s portfolio.Bath Savings Trust Co boosted its stake in PFE in the latest quarter, The investment management firm added 1,311 additional shares and now holds a total of 19,962 shares of Pfizer which is valued at $648,765. Pfizer makes up approx 0.21% of Bath Savings Trust Co’s portfolio.Ct Financial Advisors reduced its stake in PFE by selling 1,552 shares or 7.08% in the most recent quarter. The Hedge Fund company now holds 20,358 shares of PFE which is valued at $649,217. Pfizer makes up approx 0.38% of Ct Financial Advisors’s portfolio.Private Asset Management Inc boosted its stake in PFE in the latest quarter, The investment management firm added 1,328 additional shares and now holds a total of 565,456 shares of Pfizer which is valued at $18,032,392. Pfizer makes up approx 3.29% of Private Asset Management Inc’s portfolio.
On the company’s financial health, Pfizer reported $0.53 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.36. The company had revenue of $14047.00 million for the quarter, compared to analysts expectations of $13595.19 million. The company’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.
Many Wall Street Analysts have commented on Pfizer. Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.Morgan Stanley Resumed Pfizer on Apr 7, 2016 to “Equal-Weight”, Price Target of the shares are set at $35.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.